In vivo modeller for utvikling av ny leukemibehandling
- Prosjektnummer
- 911182
- Ansvarlig person
- Emmet McCormack
- Institusjon
- Universitetet i Bergen
- Prosjektkategori
- Forskerutdanning - postdoc
- Helsekategori
- Hematology
- Forskningsaktivitet
- Translasjonsforskning
In vivo optical imaging of acute myeloid leukemia by green fluorescent protein: time-domain autofluorescence decoupling, fluorophore quantification, and localization.
Mol Imaging 2007 May-Jun;6(3):193-204.
PMID: 17532885
Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients.
Eur J Haematol 2007 Sep;79(3):210-25. Epub 2007 jul 26
PMID: 17655707
Immunotherapy in chronic lymphocytic leukemia.
Cancer Immunol Immunother 2006 Feb;55(2):185-7. Epub 2005 jul 7
PMID: 16001162
Is targeted chemotherapy an alternative to immunotherapy in chronic lymphocytic leukemia?
Cancer Immunol Immunother 2006 Feb;55(2):221-8. Epub 2005 jul 21
PMID: 16034559
Animal models of acute myelogenous leukaemia - development, application and future perspectives.
Leukemia 2005 May;19(5):687-706.
PMID: 15759039
Proteomics in acute myelogenous leukaemia (AML): methodological strategies and identification of protein targets for novel antileukaemic therapy.
Curr Drug Targets 2005 Sep;6(6):631-46.
PMID: 16178797
Discrimination and Quantification of Spectrally Similar Near-Infrared Probes by Time-Domain (TD) Optical Imaging in Acute Myeloi
Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 4319
Synergistic Anti-Leukemic Effect of Protein Kinase A Activator and PPAR{gamma} Agonist Is Independent of Bcl-2 Status
Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 4200.
Development of a near infrared reporter system for in vivo imaging
Mol. Imaging (Joint Molecular Imaging Conference Abstracts) Sept 2007; 1: 118
Development and evaluation of labeled antibodies as optical contrast reagents in acute myeloid leukemia (AML)
Mol. Imaging (Joint Molecular Imaging Conference Abstracts) Sept 2007; 1: 223
In vivo optical imaging of p53 specific targeted therapy in Acute Myeloid leukaemia
Mol. Imaging (Joint Molecular Imaging Conference Abstracts) Sept 2007; 1: 299
Targeting and Visualisation of Specific Tumour Associated Antigens by
In Vitro Molecular Imaging 2007
Multimodality In Vivo Optical Imaging of Acute Myeloid Leukaemia (AML): Auto-Fluorescence De-Noising, Fluorophore Quantification
Young Investigator Award*, Society of Molecular Imaging, Hawaii, 2006. *Joint First Place.
Multimodality In Vivo Optical Imaging of Acute Myeloid Leukaemia (AML): Auto-Fluorescence De-Noising, Fluorophore Quantification
Molecular Imaging. 2006; 5(3): 444
In Vivo Optical Imaging with eXplore Optix
BCCR Solstrand, Bergen 2006
In Vivo Optical Imaging:Principles and Functional Imaging of Cancer
Trinity College Dublin, Ireland 2006
In Vivo Optical Imaging with eXplore Optix
University of Toronto, Canada 2006
In vivo optical imaging with eXplore Optix
Advanced Technologies in Biomedical Imaging, Helsinki, 2006
In Vivo Imaging of Acute Myeloid Leukaemia (AML): Preclinical Screening and Development of molecular Therapeutics
IGLD Symposium, Gottingen, Germany 2006
In Vivo Imaging of Acute Myeloid Leukaemia (AML). Preclinical Screening and Development of Molecular Therapeutics
BCCR Solstrand, Bergen 2005
In Vivo Imaging of Acute Myeloid Leukaemia (AML). Preclinical Screening and Development of Molecular Therapeutics
7th NorFa p53/Cell Cycle Workshop, Falsterbo, Sweden 2005
In Vivo Imaging of Acute Myeloid Leukaemia (AML). Preclinical Screening and Development of Molecular Therapeutics
Amersham Biosciences Symposium, Tokyo, Japan 2005
In Vivo Imaging of Acute Myeloid Leukaemia (AML). Preclinical Screening and Development of Molecular Therapeutics
Amersham Biosciences Symposium, Osaka, Japan 2005
In Vivo Imaging of Acute Myeloid Leukaemia (AML). Preclinical Screening and Development of Molecular Therapeutics
Seoul National University, Seoul, Korea 2005
In Vivo Imaging of Acute Myeloid Leukaemia (AML). Preclinical Screening and Development of Molecular Therapeutics
KCCH, Seoul, South Korea 2005
In Vivo Imaging of Acute Myeloid Leukaemia (AML). Preclinical Screening and Development of Molecular Therapeutics
NCC , Seoul , South Korea 2005
In Vivo Imaging of Acute Myeloid Leukaemia (AML). Preclinical Screening and Development of Molecular Therapeutics
Imperial College of Medicine, Hammersmith, London, Great Britian 2005
In Vivo Imaging of Acute Myeloid Leukaemia (AML). Preclinical Screening and Development of Molecular Therapeutics
GE Global research Center, Munich, Germany 2005
In Vivo Imaging of Acute Myeloid Leukaemia (AML). Preclinical Screening and Development of Molecular Therapeutics
GE Global research Center, Munich, Germany 2005
In Vivo Imaging of Acute Myeloid Leukaemia (AML). Preclinical Screening and Development of Molecular Therapeutics
Imperial College of Medicine, Hammersmith, London, Great Britian 2005
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til Faglig rapportering, Helse Vest